Kornimate/medical-research-clean huggingface dataset:
analgesic effect of resistance training for breast cancer survivors

Conditions: Breast Cancer; Surgery; Chemotherapy Effect; Radiotherapy Side Effect; Pain, Chronic

Summary: persistent pain after treatment for breast cancer is a major clinical problem, affecting 25-60 % of the patients and is a source of considerable physical disability and psychological distress. thus, the development of novel interventions to improve pain management for these patients is of clinical importance. resistance training (rt) is a promising tool to combat a variety of undesirable adverse effects due to breast cancer treatment. further, research suggests that it may also be able to provide pain-relieving benefits. hypothesis: resistance training will improve pain perception and physical function in the short- and long term compared to a non-training control group.

breast cancer is the most common cancer in women worldwide with more than a million new cases diagnosed every year \[1\]. fortunately, due to better treatment options, the population of long-term survivors is increasing. this poses new demands for knowledge on how to manage late effects to the treatment regimen. persistent pain after treatment for breast cancer is a common and underestimated problem as well as it can be a source of considerable physical disability and psychological distress \[2\]. hence, the development of novel interventions to improve pain management is of high clinical relevance. resistance training (rt) is a promising clinical therapeutic tool to improve a variety of adverse effects to breast cancer treatment \[3\] and may provide several pain-relieving benefits \[4\]. however, the efficacy of this modality for managing persistent pain after breast cancer treatment is currently unclear. therefore, the purpose of this project is to investigate if individualized rt can modulate persistent pain after breast cancer treatment, thereby improving our understanding of how this modality may benefit patients and contribute to clinical guidelines for pain management in this clinical population.

Eligibility criteria:
inclusion criteria: * primary diagnosis of breast cancer (grades i-iiia). * adult women at least 18 years of age. * having received breast cancer treatment (i.e. surgery and possible adjuvant chemo and/or radiotherapy) at least 18 months before the start of the study. * self reported pain in the areas of the breast, shoulder, axilla, arm and/or side of body with an intensity of ≥ 3 on a numeric rating scale (0 = no pain, 10 = worst pain imaginable). * no signs of cancer recurrence. * reading, writing and speaking danish. exclusion criteria: * breast surgery for cosmetic reasons or prophylactic mastectomy. * bilateral breast cancer. * lymphedema. * other chronic pain conditions (e.g., rheumatoid arthritis). * previous diagnosis of fibromyalgia syndrome.

Keywords: persistent pain breast cancer treatment physical function quality of life resistance training analgesic effect of resistance training of persistent pain after breast cancer (antrac)
psoriatic inflammation markers predictive of response to adalimumab

Conditions: Psoriasis Vulgaris

Summary: the objective is to compare the initial skin inflammatory transcriptomic profile of psoriatic patient responder to adalimumab therapy (defined as the achievement of a psoriasis area and severity index 75 response at 16 weeks) with the transcriptomic profile of patient non-responder to adalimumab therapy (defined as the non-achievement of a psoriasis area and severity index 50 response at 16 weeks) to identify differentially expressed genes in order to define predictive markers of response to the treatment.


Eligibility criteria:
inclusion criteria: * chronic plaque psoriasis involving at least 10% of body surface area, with a pasi score \>10, * negative pregnancy test for women of childbearing potential, and use of an effective method of contraception, * pretreatment assessment to identify contraindications to anti-tumor necrosis factor-alpha therapy (chest x-ray and intradermal reaction (detection of latent tuberculosis), * anti-tumor necrosis factor-alpha treatment with adalimumab has been prescribed exclusion criteria: * classical exclusion criteria for adalimumab therapy (hypersensitivity to the product, severe heart failure, abscess, tuberculosis or other opportunistic infection), * history of demyelinating disease, any unstable medical condition, patients with recurrent serious infections , history of cardiovascular or cerebrovascular disease , history of cancer * patients not having tuberculosis prophylaxis as per local guidelines for latent tuberculosis, or patients non-treated active tuberculosis * ongoing pregnancy or breastfeeding * absence of written consent, * prior treatment with one of the following anti-psoriatic treatments: biologics during the 3 months prior baseline visit, other systemic treatment during the 4 weeks prior baseline visit or topical therapy during the 2 weeks prior baseline visit.
influence of physical therapy for foot and ankle in the gait of individuals with diabetic neuropathy

Conditions: Diabetic Neuropathy With Loss of Sensation; Foot and Ankle Muscle Weakness; Foot and Ankle Range of Movement Restriction

Summary: the hypothesis is that a physical therapy intervention for foot and ankle of diabetic neuropathic individuals would affect positively the way they walk, lowering the harmful forces that these segments receive, that are associated mainly with lower range of movement, muscle weakness and loss of sensation. the participants will be randomly assigned into control group (regular treatment prescribed by their medical group) or into treatment group, that will receive 12 weeks of physical therapy intervention, twice a week, for 45 minutes each session. this will aim for increasing foot and ankle range of movement, muscle strength and improving sensory inputs.

in this study, were included subjects diagnosed with diabetic neuropathy, aged between 45 and 65 years old. we aimed to assess the effect of a physical therapy program on biomechanics of lower limbs during gait.

Eligibility criteria:
inclusion criteria: * diabetes mellitus type 1 or 2 diagnosed for at least seven years * body mass index ranging 18.5-29.9 kg/m2 (normal and overweight classifications) * diabetic polyneuropathy diagnosed by the medical care center: score higher than 2 out of 13 in the michigan neuropathy screening instrument (mnsi) questionnaire, indicating the presence of at least two diabetic polyneuropathy symptoms; score higher than 1 out of 10 for physical assessment of the mnsi instrument, but always including impaired vibration perception * ability to walk independently in the laboratory exclusion criteria: * ulceration not healed for at least 6 months * partial or total foot amputation * receiving any physiotherapy intervention or offloading devices * neurological or orthopedic impairments * major vascular complications * severe retinopathy * severe nephropathy
the effects of non-invasive neuromodulation on illness awareness in schizophrenia

Conditions: Schizophrenia; Anosognosia

Summary: this study aims to determine the clinical and functional imaging effects of serial cvs on illness awareness in schizophrenia. specifically, the investigators aim to: 1. determine if twice-daily cvs for 4 weeks will improve illness awareness compared to the sham condition in participants with schizophrenia. illness awareness will be assessed at pre- and post-cvs, and weekly thereafter for 4 weeks. 2. examine changes in brain network activity (blood oxygen level dependent-bold in response to an illness awareness task) pre- and post-cvs. this will serve as a biomarker to rigorously test whether repeated cvs engages the ppa associated with illness awareness.

the proposed study employs a novel approach to determine the clinical and functional imaging effects of cvs on illness awareness in schizophrenia - a significant contributor to medication non-adherence and poor treatment outcomes, and arguably the most treatment resistant manifestation of the disorder. cvs is a traditionally safe and non-invasive method of vestibular stimulation that will be used in conjunction with a neuroimaging biomarker to measure brain changes associated with cvs and illness awareness. the results of this study will provide solid evidence for larger treatment-controlled effectiveness studies to determine if cvs is a practical means of producing lasting effects on illness awareness in individuals with schizophrenia or whether maintenance cvs treatment is required.

Eligibility criteria:
inclusion criteria: 1. male or female inpatients or outpatients ≥ 18 years of age 2. having a dsm-v diagnosis of schizophrenia or schizoaffective disorder 3. voluntary and capable of consenting to participation in the research study 4. fluent in english 5. moderate-to-severe lack of illness awareness ≤7 on the vagus-sr, which corresponds to a rating of ≥3 on panss g12 insight and judgment item) 6. on a stable dose of antipsychotic and other concomitant medications for at least 2 months, and unlikely to undergo changes in dose during the study exclusion criteria: 1. unwilling or unable to consent to the study 2. use of hearing aids or cochlear implants, chronic tinnitus, temporomandibular joint disease 3. had eye surgery within the previous three (3) months 4. ear surgery within 6 months prior to entering the study 5. active ear infection or perforated tympanic membrane 6. diagnosis of vestibular dysfunction 7. unstable medical illness or any concomitant major medical or neurological illness, including a history of cardiovascular disease and seizures 8. acute suicidal and/or homicidal ideation 9. formal thought disorder rating ≥4 on panss item p2 10. dsm-v substance dependence (except caffeine and nicotine) within one month prior to entering the study 11. positive urine drug screen at the screening visit 12. metal implants or a pacemaker that would preclude the mri scan 13. pregnancy

Keywords: non-invasive neuromodulation illness awareness magnetic resonance imaging medical device
ultrasound quantification of liver fat

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: the investigators plan a prospective study designed to evaluate the accuracy of a new ultrasound method for quantification of liver fat content.

mri proton density fat fraction (pdff) will serve as the reference standard for liver fat fraction measurements. the strength of agreement between ultrasound derived fat fraction (udff) and pdff will be the outcome of interest for this study.

Eligibility criteria:
inclusion criteria: * patients 16 years of age or older with known fatty liver disease (based upon prior mri or ultrasound), or at risk for fatty liver disease (obese). exclusion criteria: * subject under the age of 16 * pregnant subject * subjects who cannot cooperate with performance of the ultrasound exam * subjects who cannot cooperate with performance of the mri exam * subjects who have contraindications to mri * subjects who might require sedation or anesthesia to undergo study imaging
product preference with systane compared to artificial tears on frequency of drop use

Conditions: Dry Eye

Summary: the objective of this study was to evaluate the effect of systane® compared to marketed artificial tears on the frequency of drop use.


Eligibility criteria:
inclusion criteria: * subjects age 18 (minimum); reported history of dry eye syndrome in both eyes; tfbut ≤ 7 seconds in at least 1 eye at visit 1; ≥ 1+ fluorescein staining score in any region in at least 1 eye at visit 1; desire to use an artificial tear substitute for dry eye symptoms at least 4 times per day at visit 1 and visit 2. exclusion criteria: * age less than 18 years
strategic screening for infectious diseases (tuberculosis, hiv, hbv, hcv) amongst migrants in france

Conditions: HIV; Hepatitis C; Hepatitis B; Tuberculosis

Summary: to evaluate the efficacy of a new screening for infectious diseases: tuberculosis, hiv, hbv and hcv, based on risk factors questionnaires (tb screen for tuberculosis and trod screen for hiv and hepatitis) amongst a population of legal migrants during their mandatory medical check-up. this study aims for a global improvement of screening and care for migrants.

in france, the prevalence of infectious diseases such as tuberculosis, hiv/hbv/hcv is high amongst migrants originating from certain countries, hence the official guidelines recommending targeted testing. the rapid testing devices (trod) give immediate results and reduce missed opportunities. however their use is not yet widespread and migrant populations remain insufficiently tested. regarding the unaids 90-90-90 goal, france is failing the screening part of the treatment cascade, while 90% of patients are treated and have undetectable viral load. risk scores based on the best known risk factors for these infections (hiv/hbv/hcv) have previously been developed. they have helped build a pilot of a new unique questionnaire: trod screen. an electronic survey, called tb screen, was designed to screen for tuberculosis amongst asylum seekers in switzerland and validated. this survey enables to detect signs of active tuberculosis and may replace the use of pulmonary radiography, thus reducing exposure to x-rays. it is a prospective multi-centric observational study validating screening tests for hiv/hbv/hcv in two phases: * phase 1: a risk score will be validated, including a qualitative study analyzing its acceptability * phase 2: its performance will be compared with that of a screening targeted based on the country of origin the phase 1 and phase 2 will include respectively 10.000 and 5000 participants. for tuberculosis, the efficacy of the improved version of tb screen will be compared with a systematic radiography. participation to this study will be voluntary and independent from the delivery of a residence permit. participants will be informed of it and will systematically receive information about prevention of those infectious diseases.

Eligibility criteria:
inclusion criteria: * migrants undergoing the routine medical visit * giving informed consent (oral consent) exclusion criteria: * asylum seekers * persons not understanding the questionnaire * persons aware of their hiv, hbv or hcv positive status
double-blind naltrexone in kleptomania

Conditions: Kleptomania

Summary: the goal of the proposed study is to evaluate the efficacy and safety of naltrexone in kleptomania.

the proposed study will consist of 8 weeks of treatment with either naltrexone or placebo in 20 subjects with kleptomania. the hypothesis to be tested is that naltrexone will be effective in reducing the urges to steal in patients with kleptomania. the proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Eligibility criteria:
inclusion criteria: 1. men and women age 21-75 2. current dsm-iv kleptomania. exclusion criteria: 1. unstable medical illness or clinically significant abnormalities on prestudy laboratory tests or physical examination 2. history of seizures 3. myocardial infarction within 6 months 4. current pregnancy or lactation, or inadequate contraception in women of childbearing potential 5. clinically significant suicidality 6. current or recent (past 3 months) dsm-iv substance abuse or dependence 7. illegal substance within 2 weeks of study initiation 8. initiation of psychotherapy or behavior therapy from a mental health professional for the treatment of kleptomania within 3 months prior to study baseline 9. initiation of a psychotropic medication within 2 months prior to study inclusion 10. previous treatment with naltrexone 11. treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline.

Keywords: compulsive shoplifting kleptomania compulsive stealing
steroid titration against mannitol in asthma

Conditions: Asthma

Summary: the investigators hypothesise that titration of asthma medication against mannitol challenge results will reduce the number of mild asthma exacerbations, in one year, when compared with titration against bts guidelines. to test this hypothesis the investigators propose a primary care, parallel treatment, patient blinded study in which matched groups of asthmatic patients will be treated in accordance either with bts guidelines or with our treatment algorithm dependent on mannitol challenge result. purpose of the study is to evaluate the efficacy of a treatment algorithm based on the measurement of airway hyperresponsiveness to mannitol challenge, a surrogate marker of airway inflammation, in the long term treatment of asthma in comparison to bts guidelines.


Eligibility criteria:
inclusion criteria: * male or female asthmatics aged \>/= 16 years * females must be non pregnant and non lactating * fev1 \>/= 50% predicted * mannitol pd10 \</= 635 mg at end of step down period * no recent exacerbations of asthma requiring oral prednisolone in the previous 3 months * able to perform all the techniques necessary to carry out the challenge testing and lung function and compliant with taking the study medication * good inhaler technique which will be reinforced at each study visit exclusion criteria: * male or female patients aged 15 or below * fev1 \</= 50% predicted * patients who are currently taking a pulse of oral corticosteroids * patients with the following concomitant illnesses:bronchiectasis, allergic bronchopulmonary aspergillosis, copd, heart failure, pulmonary fibrosis, rhino-sinusitis with polyps * immunocompromised patients * patients with recurrent lrti * patients with documented aspirin induced asthma on lrtas * pregnancy * known or suspected hypersensitivity to ics or other excipients of the mdis * hiv/hepatitis b or c positive
observational study of hand function after distal transradial access for angiography

Conditions: Radial Artery Occlusion; Nerve Injury

Summary: traditionally, coronary angiograms are performed through the radial artery which is accessed above the palm of the 'right' hand. in recent years, some cardiologists are performing this procedure from the back of the wrist in as the radial artery courses through the anatomical snuffbox (distal radial access). the aim of this study is to determine the prevalence of hand dysfunction following coronary angiography via the distal radial artery.

in this multi centre observational registry, we will recruit patients undergoing planned invasive coronary angiography. inclusion criteria include: 1. age ≥ 18 years. 2. the distal radial artery must be palpable and non-occlusive flow must be confirmed by doppler ultrasound. 3. patient should be able to comply with the protocol. 4. provide written informed consent before study participation. the primary endpoint is the overall prevalence of hand dysfunction defined as any significant reduction from baseline score in any of the following five domains: dash score levine katz score vas score sensory function pinch grip strength. specifically hand function will be assessed at 4 time points using simple tests of hand strength, sensation and ultrasound to assess the arterial latency.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. the distal radial artery must be palpable and non-occlusive flow must be confirmed by doppler ultrasound. 3. patient should be able to comply with the protocol. 4. provide written informed consent before study participation. exclusion criteria: 1. obligatory femoral or forearm radial access 2. previous ipsilateral forearm radial artery occlusion. 3. undergoing another procedure involving the ipsilateral radial artery, performed between the index procedure and the follow-up date. 4. enrolment in another study that competes or interferes with this study. 5. poor clinical condition like cardiogenic shock, that prohibits pre- and postprocedural function tests. 6. any other condition which, in the opinion of the investigator or operator, may pose a significant hazard to the subject if he or she is enrolled in the study. 7. co-morbidity that excludes patient follow-up.

Keywords: invasive coronary angiography distal transradial arterial access anatomical snuffbox dtra dra distal radial radial artery occlusion
study on allopregnanolone and depression in perimenopausal women

Conditions: Depression

Summary: this study aims to identify how the progesterone metabolite allopregnanolone affects behavior and neurobiology that may underlie perimenopausal depression.

midlife women are burdened with depression risk that is at least partly attributed to changing reproductive steroid dynamics across a prolonged reproductive transition. the investigators hypothesize that declining endogenous allopregnanolone (allo) levels across the menopause transition underlies perimenopausal depression. this mechanistic trial aims to amplify the contrast between lower endogenous allo levels in perimenopausal women and higher levels experimentally induced by exogenous allo. this will be achieved by using the exogenous allo treatment, brexanolone, which is fda-approved to treat depression in postpartum patients, in a randomized, double-blind, parallel-arm, placebo-controlled trial. by manipulating allo levels together with key measurement of depression domains, this study harnesses the endocrine biology of perimenopause to explicate behavioral and neurobiological mechanisms underlying depression in perimenopausal women.

Eligibility criteria:
inclusion criteria: * healthy perimenopausal women ages 40 to 60 years * depressive symptoms * able to read arabic numerals and perform simple arithmetic * able to provide written informed consent exclusion criteria: * use of medications to treat depression * systemic hormone therapy * contraindicated medications with brexanolone * other psychiatric illnesses that are considered to be primary * current suicidal ideation * active substance use disorders * unstable medical conditions * obstructive sleep apnea or other primary sleep disorders * abnormal hepatic and renal function * known allergy to progesterone, exogenous allopregnanolone, or brexanolone * history of head injury resulting in loss of consciousness \> 20 min * inability to comply with barrier contraceptive methods * known intellectual disability * investigator judgement that study participation constitutes substantial risk given medical or psychiatric condition * current or recent participation in clinical trial expected to interfere with risk of or interpretation of study data * inability to comply with study procedures